Angelini Pharma’s Post

In partnership with The European House-Ambrosetti, we launched Headway: A new roadmap in Brain Health, a project that aims to create a common ground for strategic reflection and dialogue on Epilepsy and Mental Health, as experienced from different European perspectives. Today 1st July, Headway is in Helsinki, welcoming local and global experts to talk about the implementation of the Intersectoral Global Action Plan on epilepsy & other neurological disorders (IGAP), with a special focus on how to break the barriers of stigma, fostering inclusion and rights for people with epilepsy. #AngeliniPharma #EveryStepCloser #WithYouInMind

Our Symposium “The fine line between under treatment and over treatment in uncontrolled epilepsy”, part of the European Academy of Neurology Congress 2024 in Helsinki, has just finished. Dr. Angel Aledo-Serrano has explored the topic of under treatment and the missed opportunities for reducing the seizure burden. #AngeliniPharma #EveryStepCloser #WithYouInMind #EAN2024

Today, we’re at the European Academy of Neurology Congress 2024 in Helsinki, Finland. Our Symposium “The fine line between under treatment and over treatment in uncontrolled epilepsy” is starting in a few hours and it will be chaired by Professor and Chief Physician Jukka Peltola. Prof. Peltola is focusing on “How to balance patient needs in the shifting epilepsy management.” #AngeliniPharma #EveryStepCloser #WithYouInMind #EAN2024 

We're proud to announce the launch of our second crowdsourcing campaign in partnership with Wazoku. This Open Innovation Challenge aims to identify innovative Drug Delivery Systems (DDS) and Treatments Approaches to significantly improve the lives of people with epilepsy, especially elderly and pediatric patients. With 50 million people worldwide affected by epilepsy, non-adherence to anti-seizure medication among adult patients ranges from 29 to 39%, and is even lower in elderly and pediatric populations. Identifying new options to increase adherence is vital to the epilepsy community, and research is key. Researchers, scientists, and PhD students: we need your help! If you have novel approaches to using available anti-seizure medications for patients with epilepsy, join the challenge and contribute. The research journey never ends!   The challenge closes on August 26. Good luck! To know more: https://lnkd.in/dJvgkyjr #AngeliniPharma #EveryStepCloser #WithYouInMind

We’re proud to announce that in a few days we will be joining the European Academy of Neurology Congress 2024 in Helsinki, Finland, to champion neurological excellence and epilepsy care. On Sunday 30th June, as Angelini Pharma, we will hold a Symposium entitled: “The fine line between under treatment and over treatment in uncontrolled epilepsy”. Together with Professor and Chief Physician Jukka Peltola, MD PhD Angel Aledo-Serrano and MD PhD Magdalena Bosak, we will explore new perspectives in epilepsy treatment. To know more: https://lnkd.in/dmnEvp8f #AngeliniPharma #EveryStepCloser #WithYouInMind #EAN2024

Yesterday, we held a Symposium dedicated to #HeatTherapy in sports, as part of the GOTS Congress in Nuremberg.   With Prof. Dr. Jürgen Freiwald we explored the different benefits that we can expect from heat therapy for athletes. #AngeliniPharma #EveryStepCloser 

Later today, we will hold a special Symposium dedicated to #HeatTherapy in sports, as part of the GOTS Congress in Nuremberg. In particular, with Dr. Thilo Hotfiel we will talk about on-field management and the different roles of cold and heat therapy. #AngeliniPharma #EveryStepCloser

On June 20, we will participate in the GOTS Congress in Nuremberg, holding a special Symposium dedicated to #HeatTherapy in sports. Musculoskeletal pain is indeed often diagnosed on several body parts of athletes, with the neck and back being the most frequent sites of pain (31%), followed by the knee (25%), hip (20%) and shoulders (15%). Prof. Thilo Hotfiel and Prof. Jurgen Freiwald will delve into the benefits of heat therapy in the sports context, also exploring the different roles of heat and cold therapy. #AngeliniPharma #EveryStepCloser

According to the World Health Organization (WHO), schizophrenia affects approximately 24 million people worldwide, which is about 1 in 300 people or 0.32%. Of these, about 37% are affected by severe stigma and negative stereotypes. Today, on World Schizophrenia Awareness Day, it is crucial to stand against stigma and discrimination, raising awareness and fighting misinformation about this pathology. To shed some light on the matter, on our blog we’re dispelling six schizophrenia myths through a dedicated fact-checking and debunking report. https://lnkd.in/epBZXKEj #AngeliniPharma #EveryStepCloser #WithYouInMind #WorldSchizophreniaDay